• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于正电子发射断层扫描代谢成像的2-脱氧-2-[¹⁸F]氟-D-葡萄糖的区域分布

Regional distribution of 2-deoxy-2[18F]-fluoro-D-glucose for metabolic imaging using positron emission tomography.

作者信息

Alagona P, Hart D T, Eikman E A

机构信息

St. Joseph's Positron Center, Medical Divison, Tampa, FL 33607-4227.

出版信息

Int J Card Imaging. 1994 Jun;10(2):137-43. doi: 10.1007/BF01137709.

DOI:10.1007/BF01137709
PMID:7963752
Abstract

Radiopharmaceutical availability is one of the reasons dissemination and growth of clinical PET imaging remains problematic. A 'regional' cyclotron-radiopharmacy facility for the production of the positron emitting radionuclide 2-deoxy-2[18F]-fluoro-D-glucose (FDG), has been operational for over 2 years and supplies this radiopharmaceutical to five camera facilities, four distant and one on-site. The RDS 11 MeV cyclotron is capable of dual bombardment of targets yielding 60 GBq (1600 mCi) of F-18 in a 90 minute period. F-18 labelled FDG is produced by an automated synthesis module yielding 22.2 GBq (600 mCi) FDG. The PET radiopharmacy is required to perform extensive quality assurance activities including a number of tests to insure final product and safety. [18F]FDG is shipped in unit dose vials, 6 ml, two per shielded container, meeting Department of Transportation (DOT) specifications (43 x 43 cm cubes, styrofoam packing, 22 lb. lead shield). This adheres to regulations requiring no more than 200 millirem per hour (mR/Hr) exposure at the container surface, and 10 mR/hr at a distance of 1 meter. Total transport time, utilizing private air and ground couriers, to distant facilities is approximately 100-120 minutes. Based on patient scheduling and protocol used, allowing 45-60 minutes between dose administrations, and availability of 22.2 GBq (600 mCi), 20-22 unit doses can be supplied, divided and shipped in a number of ways. The regional-commercial distribution of PET radiopharmaceuticals, specifically [18F]FDG, is feasible. This provides availability of metabolic imaging at sites distant to radiopharmaceutical production.

摘要

放射性药物的可获得性是临床正电子发射断层显像(PET)成像的传播和发展仍然存在问题的原因之一。一家用于生产正电子发射放射性核素2-脱氧-2-[18F]-氟-D-葡萄糖(FDG)的“区域”回旋加速器-放射性药物设施已经运行了两年多,并向五个显像设备供应这种放射性药物,其中四个在远处,一个在现场。RDS 11 MeV回旋加速器能够对靶材进行双重轰击,在90分钟内产生60 GBq(1600 mCi)的F-18。F-18标记的FDG由一个自动合成模块生产,产量为22.2 GBq(600 mCi)。PET放射性药物药房需要开展广泛的质量保证活动,包括多项测试以确保最终产品质量和安全性。[18F]FDG以单剂量小瓶包装运输,每瓶6 ml,每个屏蔽容器装两瓶,符合美国运输部(DOT)的规范(43×43 cm立方体,泡沫塑料包装,22磅铅屏蔽)。这符合相关规定,即容器表面的辐射暴露不超过每小时200毫雷姆(mR/Hr),在1米距离处为10 mR/hr。利用私人航空和地面快递将药物运送到远处设施的总运输时间约为100 - 120分钟。根据患者的日程安排和所用方案,给药间隔为45 - 60分钟,且有22.2 GBq(600 mCi)的可用剂量,可提供20 - 22个单剂量,并能以多种方式进行分装和运输。PET放射性药物,特别是[18F]FDG的区域 - 商业配送是可行的。这使得在远离放射性药物生产地点的地方也能进行代谢成像检查。

相似文献

1
Regional distribution of 2-deoxy-2[18F]-fluoro-D-glucose for metabolic imaging using positron emission tomography.用于正电子发射断层扫描代谢成像的2-脱氧-2-[¹⁸F]氟-D-葡萄糖的区域分布
Int J Card Imaging. 1994 Jun;10(2):137-43. doi: 10.1007/BF01137709.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
[Use of a cyclotron in the production of positron emitting radionuclides].[回旋加速器在正电子发射放射性核素生产中的应用]
Rev Esp Med Nucl. 1999 Aug;18(4):261-7.
4
Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.正电子发射断层显像-计算机断层扫描(PET-CT)、单光子发射计算机断层扫描-计算机断层扫描(SPECT-CT)和回旋加速器设施的辐射安全操作
Health Phys. 2008 Nov;95(5):554-70. doi: 10.1097/01.HP.0000327651.15794.f7.
5
New high-yield synthesis of 18F-labelled 2-deoxy-2-fluoro-D-glucose.
Int J Appl Radiat Isot. 1983 Jun;34(6):893-6. doi: 10.1016/0020-708x(83)90150-3.
6
Assessment of 18F gaseous releases during the production of 18F-fluorodeoxyglucose.18F-氟脱氧葡萄糖生产过程中18F气体释放量的评估。
Health Phys. 1991 May;60(5):657-60. doi: 10.1097/00004032-199105000-00003.
7
A shielded synthesis system for production of 2-deoxy-2-[18F]fluoro-D-glucose.一种用于生产2-脱氧-2-[¹⁸F]氟-D-葡萄糖的屏蔽合成系统。
J Nucl Med. 1981 Apr;22(4):376-80.
8
[18F]fluoride from a small cyclotron for the routine synthesis of [18F]2-fluoro-2-deoxy-D-glucose.
Int J Rad Appl Instrum A. 1986;37(5):397-401. doi: 10.1016/0883-2889(86)90095-x.
9
A "dose on demand" Biomarker Generator for automated production of [(18)F]F(-) and [(18)F]FDG.一种用于自动生产[(18)F]F(-)和[(18)F]FDG的“按需剂量”生物标志物发生器。
Appl Radiat Isot. 2014 Jul;89:167-75. doi: 10.1016/j.apradiso.2014.02.015. Epub 2014 Mar 6.
10
Positron emission tomography: radioisotope and radiopharmaceutical production.正电子发射断层扫描:放射性同位素与放射性药物的生产。
Australas Phys Eng Sci Med. 1999 Dec;22(4):136-44.

引用本文的文献

1
Radiopharmaceuticals for Skeletal Muscle PET Imaging.用于骨骼肌肉 PET 成像的放射性药物。
Int J Mol Sci. 2024 Apr 29;25(9):4860. doi: 10.3390/ijms25094860.

本文引用的文献

1
Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography.
Am J Cardiol. 1982 Apr 1;49(5):1197-207. doi: 10.1016/0002-9149(82)90045-5.
2
Assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VII. Validation of coronary flow reserve as a single integrated functional measure of stenosis severity reflecting all its geometric dimensions.在药物性冠状动脉血管扩张期间通过心肌灌注成像评估冠状动脉狭窄。VII. 冠状动脉血流储备作为反映狭窄严重程度所有几何维度的单一综合功能指标的验证。
J Am Coll Cardiol. 1986 Jan;7(1):103-13. doi: 10.1016/s0735-1097(86)80266-2.
3
Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution.使用氨基聚醚负载的亲核取代反应高效立体定向合成无载体添加的2-[¹⁸F] -氟-2-脱氧-D-葡萄糖。
J Nucl Med. 1986 Feb;27(2):235-8.
4
Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q wave infarctions: evidence for persistence of viable tissue in some infarct regions by positron emission tomography.
Circulation. 1986 May;73(5):951-63. doi: 10.1161/01.cir.73.5.951.
5
Reversibility of cardiac wall-motion abnormalities predicted by positron tomography.正电子断层扫描预测的心脏壁运动异常的可逆性。
N Engl J Med. 1986 Apr 3;314(14):884-8. doi: 10.1056/NEJM198604033141405.
6
Positron emission tomography. Prospects for clinical utility.
Invest Radiol. 1987 Jul;22(7):529-37. doi: 10.1097/00004424-198707000-00001.
7
Positron emission tomography: clinical status in the United States in 1987. ACNP/SNM Task Force on Clinical PET.正电子发射断层扫描:1987年在美国的临床应用状况。美国神经精神药理学会/核医学学会临床正电子发射断层扫描特别工作组
J Nucl Med. 1988 Jun;29(6):1136-43.
8
Application of positron emission tomography in the heart. Council on Scientific Affairs. Report of the Positron Emission Tomography Panel.
JAMA. 1988;259(16):2438-45.
9
Cyclotrons and radiopharmaceuticals in positron emission tomography. Council on Scientific Affairs. Report of the Positron Emission Tomography Panel.正电子发射断层扫描中的回旋加速器与放射性药物。科学事务委员会。正电子发射断层扫描小组报告。
JAMA. 1988 Mar 25;259(12):1854-60.
10
Surgical treatment of intractable neonatal-onset seizures: the role of positron emission tomography.
Neurology. 1988 Aug;38(8):1178-88. doi: 10.1212/wnl.38.8.1178.